ACADIA Pharmaceuticals Inc. (ACAD)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
25.50 USD
-0.72
(-2.746%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 25.31 -0.19 (-0.190%) ⇩ (July 13, 2026, 6:45 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:53 a.m. EDT
The immediate narrative is defined by a powerful regulatory tailwind; the European Commission's backing of Daybu for Rett syndrome approval has ignited a speculative frenzy, pushing the stock up nearly 20% in a week. This momentum is clearly visible in the options chain, where traders are aggressively buying calls at strikes far above the current price, betting on a continuation of this trend. While the statistical forecasting models are currently useless due to extreme noise and low reliability, the fundamental backdrop has shifted positively with the approval news. However, investors must remain cautious: the company is still burning cash with negative operating margins and a massive gap between its trailing and forward P/E multiples, indicating that the current valuation relies entirely on future growth rather than current profitability. The short-term outlook is bullish due to this catalyst-driven momentum, but the long-term investment case remains fragile given the lack of a dividend and the precarious path to sustained profitability. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.046415 |
| AutoARIMA | 0.046428 |
| AutoETS | 0.046428 |
| MSTL | 0.047582 |
| MSTL_126 | 0.065203 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 48.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.07 |
| Revenue per Share | 6.47 |
| Market Cap | 4,366,514,688 |
| Trailing P/E | 11.54 |
| Forward P/E | 28.62 |
| Beta | 0.80 |
| Profit Margins | 34.30% |
| Website | https://www.acadia.com |
As of July 11, 2026, 3:53 a.m. EDT: Speculators are positioning for a significant upside breakout, evidenced by massive open interest in out-of-the-money calls (strikes 29, 30, 31) relative to puts. The call chain shows heavy volume and open interest at strikes significantly above the current price, while put activity is sparse and concentrated at lower strikes. Implied volatility is elevated on the call side, suggesting traders expect a sharp rally driven by the recent regulatory catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.1978072 |
| Address1 | 12,830 El Camino Real |
| Address2 | Suite 400 |
| All Time High | 58.72 |
| All Time Low | 0.65 |
| Ask | 28.87 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 2,181,140 |
| Average Daily Volume3 Month | 1,717,040 |
| Average Volume | 1,717,040 |
| Average Volume10Days | 2,181,140 |
| Beta | 0.8 |
| Bid | 22.03 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 7.295 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 1 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 25.5 |
| Current Ratio | 3.587 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 26.04 |
| Day Low | 25.3 |
| Debt To Equity | 4.07 |
| Display Name | ACADIA Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Growth | -0.818 |
| Earnings Quarterly Growth | -0.808 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | 92,707,000 |
| Ebitda Margins | 0.08464 |
| Enterprise To Ebitda | 38.464 |
| Enterprise To Revenue | 3.256 |
| Enterprise Value | 3,565,850,624 |
| Eps Current Year | 0.3814 |
| Eps Forward | 0.89089 |
| Eps Trailing Twelve Months | 2.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 558 2872 |
| Fifty Day Average | 22.5246 |
| Fifty Day Average Change | 2.975401 |
| Fifty Day Average Change Percent | 0.13209562 |
| Fifty Two Week Change Percent | 19.78072 |
| Fifty Two Week High | 28.35 |
| Fifty Two Week High Change | -2.8500004 |
| Fifty Two Week High Change Percent | -0.10052911 |
| Fifty Two Week Low | 19.69 |
| Fifty Two Week Low Change | 5.8099995 |
| Fifty Two Week Low Change Percent | 0.2950736 |
| Fifty Two Week Range | 19.69 - 28.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,085,664,600,000 |
| Float Shares | 127,187,155 |
| Forward Eps | 0.89089 |
| Forward P E | 28.623062 |
| Free Cashflow | 154,138,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 796 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.61579 |
| Gross Profits | 674,448,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00322 |
| Held Percent Institutions | 0.98939 |
| Implied Shares Outstanding | 171,235,870 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. |
| Long Name | ACADIA Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 4,366,514,688 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_683713 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 375,649,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,489,804,511 |
| Number Of Analyst Opinions | 20 |
| Open | 26.04 |
| Operating Cashflow | 123,494,000 |
| Operating Margins | -0.01722 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 50.86 |
| Phone | 858 558 2871 |
| Post Market Change | -0.19000053 |
| Post Market Change Percent | -0.74510014 |
| Post Market Price | 25.31 |
| Post Market Time | 1,783,982,755 |
| Previous Close | 26.22 |
| Price Eps Current Year | 66.85894 |
| Price Hint | 2 |
| Price To Book | 3.495545 |
| Price To Sales Trailing12 Months | 3.9867742 |
| Profit Margins | 0.34298 |
| Quick Ratio | 3.273 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.7619 |
| Region | US |
| Regular Market Change | -0.719999 |
| Regular Market Change Percent | -2.74599 |
| Regular Market Day High | 26.04 |
| Regular Market Day Low | 25.3 |
| Regular Market Day Range | 25.3 - 26.04 |
| Regular Market Open | 26.04 |
| Regular Market Previous Close | 26.22 |
| Regular Market Price | 25.5 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,539,291 |
| Return On Assets | 0.03694 |
| Return On Equity | 0.37317002 |
| Revenue Growth | 0.097 |
| Revenue Per Share | 6.47 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 171,235,870 |
| Shares Percent Shares Out | 0.064 |
| Shares Short | 10,951,125 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 11,754,100 |
| Short Name | ACADIA Pharmaceuticals Inc. |
| Short Percent Of Float | 0.1014 |
| Short Ratio | 6.56 |
| Source Interval | 15 |
| State | CA |
| Symbol | ACAD |
| Target High Price | 45.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 32.65 |
| Target Median Price | 34.5 |
| Total Cash | 851,457,984 |
| Total Cash Per Share | 4.972 |
| Total Debt | 50,794,000 |
| Total Revenue | 1,095,250,048 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.21 |
| Trailing P E | 11.538462 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.31395 |
| Two Hundred Day Average Change | 2.1860504 |
| Two Hundred Day Average Change Percent | 0.09376577 |
| Type Disp | Equity |
| Volume | 1,539,291 |
| Website | https://www.acadia.com |
| Zip | 92,130 |